Takeda is presenting long-term efficacy and real-world data for Entyvio at ACG 2018 in Philadelphia Oct. 5-10.
Here's what you should know:
1. Researchers will present a retrospective multicenter cohort study of 249 patients with no prior history of taking biologic drugs for the treatment of UC or Crohn's. They observed high rates of treatment persistence, clinical remission and mucosal healing in bio-native Entyvio patients after 18 months.
2. Takeda also presented two systematic reviews and meta-analyses of 26 studies examining real-world treatment persistence and mucosal healing in patients with moderate to severe Crohn's disease taking Entyvio. After a year, about three-quarters of ulcerative colitis and two-thirds of Crohn's disease patients persisted with Entyvio treatment. Twenty-six percent of Crohn's disease patients at six months and 37 percent at 12 months experienced mucosal healing with Entyvio.
3. Researchers also conducted a time-trend analysis of utilization and outcomes across the U.S. associated with Entyvio use during the first 12 months after the drug became available. The analysis showed a shift in positioning Entyvio in the past three years in less refractory patients, in addition to a shift toward earlier use in treating ulcerative colitis compared to Crohn's disease.